 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Glucocorticoid Medications and the Risk for Cardiovascular Disease
16 November 2004 | Volume 141 Issue 10 | Page I-58
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease." It is in the 16 November 2004 issue of Annals of Internal Medicine (volume 141, pages 764-770). The authors are L. Wei, T.M. MacDonald, and B.R. Walker.
What is the problem and what is known about it so far?
Glucocorticoids (also known as steroids or corticosteroids) include medications such as beclomethasone, prednisone, prednisolone, cortisone, and hydrocortisone. Glucocorticoids are related to corticosteroid hormones produced by the adrenal glands. Doctors prescribe glucocorticoids primarily to treat inflammatory conditions that affect the lungs, skin, joints, digestive tract, eyes, or other body systems. Common diseases that frequently require treatment with glucocorticoids include asthma, inflammatory bowel disease, and some types of arthritis. Glucocorticoids generally do not cause serious side effects when patients use them in small amounts or for short durations. However, patients who require high doses or longer duration of glucocorticoid treatment can develop side effects, including weight gain, mood changes, high blood pressure, high blood sugar levels, and thinning of the bones. Some people worry that glucocorticoids' effects on blood pressure, blood sugar, and body weight put users at high risk for cardiovascular disease, such as heart attack and stroke. While glucocorticoids have been associated with higher risk for cardiovascular disease, research on the existence and strength of the link between glucocorticoids medications and cardiovascular disease is limited.
Why did the researchers do this particular study?
To study the relationship between glucocorticoid medications and cardiovascular disease.
Who was studied?
68,781 people who used glucocorticoids and 82,202 who had not. Study participants resided in Tayside, Scotland, and were registered in a National Health Service database from 1993 to 1996.
How was the study done?
The researchers used information in the database to calculate the average daily dose of glucocorticoid medications given by mouth, by inhalation, or by application on the skin over the study period. They converted the amounts of different glucocorticoids into an equivalent dose of prednisolone to make comparisons easier. They also used the database to determine whether patients had had a cardiovascular event, such as a heart attack or stroke. The researchers then examined the relationship between glucocorticoid use and cardiovascular events while controlling for other factors that might influence cardiovascular disease.
What did the researchers find?
Patients who received high-dose glucocorticoids were more than twice as likely to have had a cardiovascular event as patients who used no glucocorticoids. They defined high-dose glucocorticoid use as the equivalent of 7.5 mg of prednisolone per day or more during 1 to 5 years of follow-up. Lower doses were not associated with an increase in cardiovascular events.
What were the limitations of the study?
This study did not definitively determine that glucocorticoids themselves, not the diseases that had necessitated treatment with high-dose glucocorticoid treatment, accounted for the higher risk for cardiovascular disease.
What are the implications of the study?
Patients receiving high-dose glucocorticoids seem to have an increased risk for cardiovascular events than patients who do not use glucocorticoids. Patients and doctors should consider this risk when they weigh the benefits and risks of glucocorticoid treatment.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, and G. D. Kitas Hypertension in rheumatoid arthritis Rheumatology, May 29, 2008; (2008) ken159v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P Macfarlane, S. Forbes, and B. R Walker Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome J. Endocrinol., May 1, 2008; 197(2): 189 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Nieman, B. M. K. Biller, J. W. Findling, J. Newell-Price, M. O. Savage, P. M. Stewart, and V. M. Montori The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1526 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Rothenberg, A. D. Klion, F. E. Roufosse, J. E. Kahn, P. F. Weller, H.-U. Simon, L. B. Schwartz, L. J. Rosenwasser, J. Ring, E. F. Griffin, et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab N. Engl. J. Med., March 20, 2008; 358(12): 1215 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.I. Alexandraki, P. Makras, A.D. Protogerou, K. Dimitriou, A. Stathopoulou, D.S. Papadogias, P. Voidonikola, G. Piaditis, A. Pittas, C.M. Papamichael, et al. Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities QJM, January 1, 2008; 101(1): 31 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. F. Panoulas, K. M. J. Douglas, A. Stavropoulos-Kalinoglou, G. S. Metsios, P. Nightingale, M. D. Kita, M. S. Elisaf, and G. D. Kitas Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis Rheumatology, January 1, 2008; 47(1): 72 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Canhao, A. Cortesao, M. Cabral, J. M. Ferro, J. Stam, M.-G. Bousser, F. Barinagarrementeria, and for the ISCVT Investigators Are Steroids Useful to Treat Cerebral Venous Thrombosis? Stroke, January 1, 2008; 39(1): 105 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R Walker Glucocorticoids and Cardiovascular Disease Eur. J. Endocrinol., November 1, 2007; 157(5): 545 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tichelli, C. Bucher, A. Rovo, G. Stussi, M. Stern, M. Paulussen, J. Halter, S. Meyer-Monard, D. Heim, D. A. Tsakiris, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation Blood, November 1, 2007; 110(9): 3463 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Vandenbroucke, E. v. Elm, D. G. Altman, P. C. Gotzsche, C. D. Mulrow, S. J. Pocock, C. Poole, J. J. Schlesselman, M. Egger, and for the STROBE initiative Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration Ann Intern Med, October 16, 2007; 147(8): W-163 - W-194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sainte-Marie, A. N. D. Cat, R. Perrier, L. Mangin, C. Soukaseum, M. Peuchmaur, F. Tronche, N. Farman, B. Escoubet, J.-P. Benitah, et al. Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block FASEB J, October 1, 2007; 21(12): 3133 - 3141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Knockaert Cardiac involvement in systemic inflammatory diseases Eur. Heart J., August 1, 2007; 28(15): 1797 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fardet, J. Cabane, A. Kettaneh, C. Lebbe, and A. Flahault Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome Rheumatology, July 1, 2007; 46(7): 1102 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-G. Lofdahl, D. S. Postma, N. B. Pride, J. Boe, and A. Thoren Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD Eur. Respir. J., June 1, 2007; 29(6): 1115 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Dover, P. W. F. Hadoke, L. J. Macdonald, E. Miller, D. E. Newby, and B. R. Walker Intravascular Glucocorticoid Metabolism during Inflammation and Injury in Mice Endocrinology, January 1, 2007; 148(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Scheuer, A. G. Bechtold, and K. A. Vernon Chronic Activation of Dorsal Hindbrain Corticosteroid Receptors Augments the Arterial Pressure Response to Acute Stress Hypertension, January 1, 2007; 49(1): 127 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D H Solomon, N J Goodson, J N Katz, M E Weinblatt, J Avorn, S Setoguchi, C Canning, and S Schneeweiss Patterns of cardiovascular risk in rheumatoid arthritis Ann Rheum Dis, December 1, 2006; 65(12): 1608 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R WALKER and R. ANDREW Tissue Production of Cortisol by 11beta-Hydroxysteroid Dehydrogenase Type 1 and Metabolic Disease Ann. N.Y. Acad. Sci., November 1, 2006; 1083(1): 165 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E CHAPMAN, A. COUTINHO, M. GRAY, J. S GILMOUR, J. S SAVILL, and J. R SECKL Local Amplification of Glucocorticoids by 11beta-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Inflammatory Response Ann. N.Y. Acad. Sci., November 1, 2006; 1088(1): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Filipsson, J. P. Monson, M. Koltowska-Haggstrom, A. Mattsson, and G. Johannsson The Impact of Glucocorticoid Replacement Regimens on Metabolic Outcome and Comorbidity in Hypopituitary Patients J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3954 - 3961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. P. DA SILVA, J. W. G. JACOBS, and J. W. J. BIJLSMA Revisiting the Toxicity of Low-Dose Glucocorticoids: Risks and Fears Ann. N.Y. Acad. Sci., June 1, 2006; 1069(1): 275 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Salerno and R. Hermann Efficacy and Safety of Steroid Use for Postoperative Pain Relief. Update and Review of the Medical Literature J. Bone Joint Surg. Am., June 1, 2006; 88(6): 1361 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Wei, M J Murphy, and T M MacDonald Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs Heart, June 1, 2006; 92(6): 746 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lister, D. J. Autelitano, A. Jenkins, R. D. Hannan, and K. E. Sheppard Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: A possible role for SGK1 Cardiovasc Res, June 1, 2006; 70(3): 555 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. van der Hooft, J. Heeringa, G. G. Brusselle, A. Hofman, J. C. M. Witteman, J. H. Kingma, M. C. J. M. Sturkenboom, and B. H. Ch. Stricker Corticosteroids and the risk of atrial fibrillation. Arch Intern Med, May 8, 2006; 166(9): 1016 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F.H. van Bommel and T. R. Hendriksz Tamoxifen Therapy for Retroperitoneal Fibrosis Ann Intern Med, April 18, 2006; 144(8): 619 - 620. [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Vondracek and B. A. Hemstreet Retrospective evaluation of systemic corticosteroids for the management of acute exacerbations of chronic obstructive pulmonary disease Am. J. Health Syst. Pharm., April 1, 2006; 63(7): 645 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Bechtold and D. A. Scheuer Glucocorticoids act in the dorsal hindbrain to modulate baroreflex control of heart rate Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2006; 290(4): R1003 - R1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A P Da Silva, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Ines, E J P de Koning, F Buttgereit, M Cutolo, H Capell, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data Ann Rheum Dis, March 1, 2006; 65(3): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Small, P. W. F. Hadoke, I. Sharif, A. R. Dover, D. Armour, C. J. Kenyon, G. A. Gray, and B. R. Walker Preventing local regeneration of glucocorticoids by 11{beta}-hydroxysteroid dehydrogenase type 1 enhances angiogenesis PNAS, August 23, 2005; 102(34): 12165 - 12170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. de LEEUW, C. KALLENBERG, and M. BIJL Accelerated Atherosclerosis in Patients with Systemic Autoimmune Diseases Ann. N.Y. Acad. Sci., June 1, 2005; 1051(1): 362 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Brotman, J. P. Girod, M. J. Garcia, J. V. Patel, M. Gupta, A. Posch, S. Saunders, G. Y. H. Lip, S. Worley, and S. Reddy Effects of Short-Term Glucocorticoids on Cardiovascular Biomarkers J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3202 - 3208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Coller Leukocytosis and Ischemic Vascular Disease Morbidity and Mortality: Is It Time to Intervene? Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 658 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 High-Dose Steroids and Cardiovascular Risk Journal Watch Cardiology, January 7, 2005; 2005(107): 4 - 4. [Full Text]
|
|
|
|
|
|
Endocrinology & Metabolism News, January 2005 J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 16a - 16a. [Full Text] [PDF]
|
|
Read all Rapid Responses
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
